Cargando…

Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017

1. Familial hypercholesterolemia (FH) is an autosomal hereditary disease with the 3 major clinical features of hyper-LDL-cholesterolemia, premature coronary artery disease and tendon and skin xanthomas. As there is a considerably high risk of coronary artery disease (CAD), in addition to early diagn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harada-Shiba, Mariko, Arai, Hidenori, Ishigaki, Yasushi, Ishibashi, Shun, Okamura, Tomonori, Ogura, Masatsune, Dobashi, Kazushige, Nohara, Atsushi, Bujo, Hideaki, Miyauchi, Katsumi, Yamashita, Shizuya, Yokote, Koutaro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2018
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099072/ https://www.ncbi.nlm.nih.gov/pubmed/29877295 http://dx.doi.org/10.5551/jat.CR003

Ejemplares similares

Guidance for Pediatric Familial Hypercholesterolemia 2017
por: Harada-Shiba, Mariko, et al.
Publicado: (2018)

Factors Associated with Carotid Atherosclerosis and Achilles Tendon Thickness in Japanese Patients with Familial Hypercholesterolemia: A Subanalysis of the Familial Hypercholesterolemia Expert Forum (FAME) Study
por: Ogura, Masatsune, et al.
Publicado: (2022)

Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022
por: Harada-Shiba, Mariko, et al.
Publicado: (2023)

Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study
por: Yamashita, Shizuya, et al.
Publicado: (2022)

Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study
por: Naito, Ryo, et al.
Publicado: (2022)

Guidelines on the Clinical Evaluation of Medicinal Products for Treatment of Dyslipidemia
por: Yamashita, Shizuya, et al.
Publicado: (2020)

Homozygous Familial Hypercholesterolemia
por: Nohara, Atsushi, et al.
Publicado: (2021)

Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022
por: Harada-Shiba, Mariko, et al.
Publicado: (2023)

Achilles Tendon Thickness Assessed by X-ray Predicting a Pathogenic Mutation in Familial Hypercholesterolemia Gene
por: Tada, Hayato, et al.
Publicado: (2022)

Diagnosis and Management of Sitosterolemia 2021
por: Tada, Hayato, et al.
Publicado: (2021)

Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
por: Arai, Hidenori, et al.
Publicado: (2018)

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment
por: Yokote, Koutaro, et al.
Publicado: (2019)

Gradual dose Titration of Lomitapide may Prevent Therapeutic Delays in Patients with Homozygous Familial Hypercholesterolemia
por: Harada-Shiba, Mariko, et al.
Publicado: (2023)

Current Diagnosis and Management of Tangier Disease
por: Koseki, Masahiro, et al.
Publicado: (2021)

Familial Hypercholesterolemia and Lipoprotein Apheresis
por: Makino, Hisashi, et al.
Publicado: (2019)

Effects of a novel selective peroxisome proliferator‐activated receptor‐α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance
por: Matsuba, Ikuro, et al.
Publicado: (2018)

Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination
por: Yamashita, Shizuya, et al.
Publicado: (2019)

Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate
por: Yamashita, Shizuya, et al.
Publicado: (2021)

Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials
por: Yokote, Koutaro, et al.
Publicado: (2021)

Association between Familial Hypercholesterolemia and Serum Levels of Cholesterol Synthesis and Absorption Markers: The CACHE Study FH Analysis
por: Matsuki, Kota, et al.
Publicado: (2023)

Current Status of Familial LCAT Deficiency in Japan
por: Kuroda, Masayuki, et al.
Publicado: (2021)

Association between Achilles Tendon Softness and Atherosclerotic Cardiovascular Disease in Patients with Familial Hypercholesterolemia
por: Michikura, Masahito, et al.
Publicado: (2022)

The benign c.344G > A: p.(Arg115His) variant in the LDLR gene interpreted from a pedigree-based genetic analysis of familial hypercholesterolemia
por: Hori, Mika, et al.
Publicado: (2020)

Prospective Registry Study of Primary Dyslipidemia (PROLIPID): Rationale and Study Design
por: Tada, Hayato, et al.
Publicado: (2022)

Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels
por: Funabashi, Sayaka, et al.
Publicado: (2022)

Familial Hypercholesterolemia in Patients with Acute Coronary Syndrome: Genetic Insights from EXPLORE-J
por: Harada-Shiba, Mariko, et al.
Publicado: (2022)

Treatment Patterns and Lipid Profile in Patients with Familial Hypercholesterolemia in Japan
por: Teramoto, Tamio, et al.
Publicado: (2018)

What Arteries are Affected in Familial Hypercholesterolemia?
por: Harada-Shiba, Mariko
Publicado: (2019)

Real-World Data to Identify Hypercholesterolemia Patients on Suboptimal Statin Therapy
por: Kajinami, Kouji, et al.
Publicado: (2019)

Substantially Elevated Atherosclerotic Risks in Japanese Severe Familial Hypercholesterolemia Defined by the International Atherosclerosis Society
por: Funabashi, Sayaka, et al.
Publicado: (2021)

Impact of Familial Hypercholesterolemia Diagnosis in Real-World Data
por: Harada-Shiba, Mariko
Publicado: (2023)

The Roles of Genetic Analysis in the Diagnosis of Pediatric Patients with Familial Hypercholesterolemia
por: Harada-Shiba, Mariko
Publicado: (2022)

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017
por: Kinoshita, Makoto, et al.
Publicado: (2018)

Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia
por: Harada-Shiba, Mariko, et al.
Publicado: (2017)

Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52‐week data from the PROVIDE study
por: Araki, Eiichi, et al.
Publicado: (2019)

VLDL/LDL acts as a drug carrier and regulates the transport and metabolism of drugs in the body
por: Yamamoto, Hideaki, et al.
Publicado: (2017)

Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia
por: Doi, Takahito, et al.
Publicado: (2021)

Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE)
por: Yamashita, Shizuya, et al.
Publicado: (2021)

A Japanese case of familial hypercholesterolemia with a novel mutation in the LDLR gene
por: Nagahara, Keiko, et al.
Publicado: (2019)

Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study
por: Nohara, Atsushi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_21re9kr522endd0tqmcjmg309d